Cardiopulmonary Bypass System Market Set to Reach US$ 270.9 Million by 2033 | Future Market Insights,Inc.

The net worth of all cardiopulmonary bypass systems market sold worldwide was approximately US$ 173.9 million in 2018. The market’s projected growth, which is expected to reach a US$ 270.9 million valuation by 2033, is considerably more encouraging. A noteworthy rise from US$ 197.3 million in 2023 indicates a robust compound annual growth rate (CAGR) of 3.2% for the entire market over the forecast period ending in 2033.

The increasing frequency of cardiovascular illnesses and the growth in heart attacks are two major factors driving the increased use of cardiopulmonary bypass devices. Cardiopulmonary bypass systems have progressively gained popularity in the last two decades with the rise in heart operations globally. During cardiac procedures, it sustains and preserves the function of the heart and lungs, enabling surgeons to carry out operations safely and effectively.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5855

The demand for cardiopulmonary bypass systems is poised to increase significantly as the burden of cardiovascular disease throughout the world continues to rise. The sales of cardiopulmonary bypass systems have also been significantly influenced by the increased knowledge and its acceptability among healthcare institutions and professionals. According to FMI, it could greatly boost the revenue of market participants involved in the production of these life-saving medical equipment in the coming years.

Key Takeaways from the Global Cardiopulmonary Bypass System Market Study Report by FMI

• The adoption of cardiopulmonary bypass systems is higher in North America and Europe, with 37.2% and 27.3% global market shares in 2022.
• The combined revenue generated by the market players in the United States was nearly 33.5% of the global revenue in 2022. At the same time, Germany was able to generate only 5.8% of the global revenue share that year.
• As Asia Pacific nations continue to improve their healthcare infrastructure, there is likely to be a higher demand for cardiopulmonary bypass systems in the region. For instance, China and India are poised to witness 3.9% and 3.2% CAGRs in sales of cardiopulmonary bypass systems over the next ten years, respectively.

Competitive Landscape for the Cardiopulmonary Bypass System Market Players

Minnetronix, Transonic, MAQUET Holding, Getinge, Terumo, MicroPort, Xenios, Nipro, Eurosets, OriGen, Thoratec, Tianjin, Olympus, and Haemonetics, among others, are some top market players. These leading industries have been spending heavily on research and development, which has resulted in the release of sophisticated and feature-rich cardiopulmonary bypass systems.

Hospitals and medical facilities worldwide are adopting cardiopulmonary bypass systems into their surgical protocols, encouraging the emergence of regional players. Moreover, to take advantage of the growing demand, existing as well as new players have been increasing their presence in new emerging economies.

Recent Developments by the Cardiopulmonary Bypass System Manufacturing Industries

In October 2022, Maquet Holdings announced the release of the Cardiohelp 3, a brand-new CPB system created to replace older systems and be more effective and user-friendly. This novel cardiopulmonary bypass system has several advancements, such as a smaller, lighter pump and a more straightforward controller.

In January 2023, Medtronic announced an acquisition of CardioGenesis, a minimally invasive cardiopulmonary bypass device producer. Through this purchase, it may have access to the technology for the insertion of a catheter-based pump through a tiny incision in the patient’s chest.

Key companies:
LivaNova PLC (Sorin Group), Abbott Laboratories, Braile Biomedica, Spectrum Medical, Minnetronix Inc., Transonic, Medtronic plc., MAQUET Holding B.V. & Co. KG, Getinge AB, Terumo Corporation, MicroPort Scientific Corporation, Xenios AG, Nipro Corporation, Eurosets Srl, OriGen Biomedical, Thoratec Corporation, Tianjin Medical, Olympus Corporation, Haemonetics Corporation, etc.